Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02256969
Other study ID # 14-059H
Secondary ID
Status Completed
Phase Phase 4
First received August 13, 2014
Last updated December 19, 2016
Start date October 2014
Est. completion date August 2015

Study information

Verified date October 2014
Source Massachusetts Eye and Ear Infirmary
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or their symptoms.

The investigators are also evaluating the effects of using two (2) post-procedural medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after the MGP procedure has an effect on its outcome.


Description:

Dry eye disease is one of the most common conditions seen in ophthalmic practice and is associated with significant patient distress. Meibomian gland dysfunction (MGD) is among the most prevalent causes of dry eye disease. This condition, which is often due to obstruction of the meibomian gland orifices, may result in significant ocular irritation. Traditionally, management of MGD includes warm compress, lid hygiene, and anti-inflammatory medications. This randomized clinical trial is designed to evaluate the effects of meibomian gland probing versus sham procedure in cases with refractory MGD that do not respond to traditional treatments. Moreover, the effects of postoperative regimen will also be investigated using two different regimens. In addition to symptoms, the changes will also be evaluated in terms of clinical signs as well as in vivo confocal microscopy (IVCM) which allows study at the cellular level.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria:

- Age 18-89 years

- Willing and able to provide written informed consent

- Willing and able to comply with study assessments for the full duration of the study

- Diagnosis of meibomian gland dysfunction (MGD)

- Symptoms of MGD such as foreign body sensation, burning, stinging, light sensitivity for at least 3 months

- Persistent symptoms despite at least 3 months of medical management including lid hygiene, warm compress, and use of topical and systemic therapy, or contraindication to systemic therapy

- Presence of lid tenderness on the upper lids in both eyes

- Tear break-up time (TBUT) of <10 seconds

- In good stable overall health

Exclusion Criteria:

- Active allergies to steroids, sulfacetamide, GenTeal PM Night-Time ointment, or lidocaine

- Intraocular surgery or ocular laser surgery within 1 month before enrollment

- History of ocular infection within 1 month before enrollment.

- History of increased intraocular pressure after using topical steroids (steroid responsive)

- Any condition (including language barrier) that precludes subject's ability to comply with study requirements including completion of study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Blephamide

GenTeal PM Night-Time

Procedure:
Meibomian Gland Probing
For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) will be applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine will be injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) will be used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients will initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
Sham Meibomian Gland Probing
For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) will be applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine will be injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin will be touched with the probes without actual probing of the meibomian gland orifices.

Locations

Country Name City State
United States Massachusetts Eye and Ear Infirmary Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts Eye and Ear Infirmary

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptoms Symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire and the Symptom Assessment iN Dry Eye (SANDE) questionnaire 1 Month No
Primary Tear Break Up Time (TBUT) TBUT will be assessed using fluorescein staining 1 month No
See also
  Status Clinical Trial Phase
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT04884243 - Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Terminated NCT02596919 - Fast Infrared Meibography (Photography) N/A
Completed NCT01207752 - The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction N/A
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT03652051 - A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED) Phase 2
Recruiting NCT03767530 - Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction N/A
Active, not recruiting NCT05577910 - Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD N/A
Completed NCT04889950 - Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction N/A
Recruiting NCT06004895 - Mechanisms of Light-based Therapies for Dry Eye Disease N/A
Completed NCT04147962 - Intense Pulsed Light in Meibomian Gland Dysfunctions
Recruiting NCT05089591 - Intense Pulsed Light in Meibomian Gland Dysfunction N/A
Completed NCT04500821 - Evaluation of the LipiFlow System With a New Activator N/A
Completed NCT03318874 - Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction Phase 4
Completed NCT06278584 - iLux Treatment for Meibomian Gland Dysfunction N/A
Recruiting NCT04052841 - Morphological Analysis of Meibomian Glands N/A
Completed NCT05028491 - The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients
Completed NCT03617315 - Crosslinked Hyaluronic Acid With Liposomes and Crocin in Dry Eye N/A